Vita 34 AG (WKN A0BL84), a pioneer in the storage of stem cells from umbilical cord blood and tissue, as well as a specialist in cryo-preservation, announces that the analysts at Close Brothers Seydler Research AG (CBS Research) have started coverage of the Vita 34 stock. In their initial research report, published today, the analysts have expressed a buy recommendation with a target price of EUR 7.10.
The analysts identified advances in the development of therapies using stem cells from umbilical cord blood and tissue, as well as a growing number of stem cell transplantation, as major drivers of growth. The variety of applications for autologous stem cells provides a great deal of potential to the field of regenerative medicine, and should contribute to increasing storage rates. In addition, the analysts see a positive effect on revenue growth from the strategic direction of expanding international activities via partners. Additional potential is offered by the expansion of the product range. For example, the introduction of the new product "VitaPlusNabelschnur" [VitaPlusCord] should have a significant effect on the group revenues and profits of Vita 34. In all, Vita 34 will use its corporate strengths, experience and innovative power to expand its already strong market position.
Dr. André Gerth, Chairman of the Management Board of Vita 34 AG, commented on the start of coverage: "We are pleased to again be able to provide our investors with an important source of information in the form of the current stock research report from CBS Research, in order to arrive at the most objective assessment of our growth potential possible. It is, moreover, a component of our significantly enhanced investor relations strategy aimed towards increasing the transparency of our company, and convincing additional private and institutional investors of the future opportunities available to Vita 34."
The complete research report is available for download as of today on the website at www.vita34group.de in the "Investor Relations" section.
The analysts identified advances in the development of therapies using stem cells from umbilical cord blood and tissue, as well as a growing number of stem cell transplantation, as major drivers of growth. The variety of applications for autologous stem cells provides a great deal of potential to the field of regenerative medicine, and should contribute to increasing storage rates. In addition, the analysts see a positive effect on revenue growth from the strategic direction of expanding international activities via partners. Additional potential is offered by the expansion of the product range. For example, the introduction of the new product "VitaPlusNabelschnur" [VitaPlusCord] should have a significant effect on the group revenues and profits of Vita 34. In all, Vita 34 will use its corporate strengths, experience and innovative power to expand its already strong market position.
Dr. André Gerth, Chairman of the Management Board of Vita 34 AG, commented on the start of coverage: "We are pleased to again be able to provide our investors with an important source of information in the form of the current stock research report from CBS Research, in order to arrive at the most objective assessment of our growth potential possible. It is, moreover, a component of our significantly enhanced investor relations strategy aimed towards increasing the transparency of our company, and convincing additional private and institutional investors of the future opportunities available to Vita 34."
The complete research report is available for download as of today on the website at www.vita34group.de in the "Investor Relations" section.
